Zoetis - ZTS Stock Forecast, Price & News

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.

Analyst Ratings Changes

ZTS has been the topic of several recent analyst reports. Stifel Nicolaus cut their price objective on shares of Zoetis from $275.00 to $225.00 and set a "buy" rating on the stock in a report on Friday, June 24th. The Goldman Sachs Group cut their price objective on shares of Zoetis from $208.00 to $202.00 and set a "buy" rating on the stock in a report on Thursday, July 21st. William Blair restated an "outperform" rating on shares of Zoetis in a report on Friday, August 5th. StockNews.com downgraded shares of Zoetis from a "strong-buy" rating to a "buy" rating in a report on Tuesday, April 26th. Finally, Piper Sandler initiated coverage on shares of Zoetis in a report on Monday, July 11th. They set an "overweight" rating and a $205.00 price objective on the stock. One analyst has rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, Zoetis has a consensus rating of "Moderate Buy" and an average price target of $224.14.

Zoetis Stock Performance

Zoetis stock traded up $2.49 during mid-day trading on Friday, hitting $175.67. The company had a trading volume of 1,185,214 shares, compared to its average volume of 1,577,425. The company has a current ratio of 2.18, a quick ratio of 1.46 and a debt-to-equity ratio of 1.14. Zoetis has a 12-month low of $154.18 and a 12-month high of $249.27. The company's fifty day moving average is $172.10 and its 200-day moving average is $180.43. The company has a market capitalization of $82.24 billion, a price-to-earnings ratio of 39.83, a P/E/G ratio of 2.96 and a beta of 0.73.

Zoetis (NYSE:ZTS - Get Rating) last released its quarterly earnings data on Thursday, August 4th. The company reported $1.20 EPS for the quarter, missing the consensus estimate of $1.22 by ($0.02). Zoetis had a return on equity of 49.03% and a net margin of 26.14%. The company had revenue of $2.10 billion during the quarter, compared to analysts' expectations of $2.03 billion. During the same quarter in the prior year, the company posted $1.19 EPS. The company's revenue for the quarter was up 7.8% on a year-over-year basis. Equities research analysts predict that Zoetis will post 5.01 EPS for the current year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 1st. Shareholders of record on Thursday, July 21st will be given a $0.325 dividend. The ex-dividend date is Wednesday, July 20th. This represents a $1.30 annualized dividend and a yield of 0.74%. Zoetis's dividend payout ratio is presently 29.48%.

Insiders Place Their Bets

In other Zoetis news, CEO Kristin C. Peck sold 9,689 shares of the company's stock in a transaction that occurred on Thursday, July 21st. The stock was sold at an average price of $180.00, for a total value of $1,744,020.00. Following the sale, the chief executive officer now owns 39,743 shares in the company, valued at approximately $7,153,740. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, Director Willie M. Reed sold 1,855 shares of the stock in a transaction that occurred on Friday, June 10th. The stock was sold at an average price of $162.31, for a total transaction of $301,085.05. Following the transaction, the director now owns 6,782 shares in the company, valued at approximately $1,100,786.42. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Kristin C. Peck sold 9,689 shares of the stock in a transaction that occurred on Thursday, July 21st. The shares were sold at an average price of $180.00, for a total value of $1,744,020.00. Following the transaction, the chief executive officer now owns 39,743 shares in the company, valued at approximately $7,153,740. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 18,356 shares of company stock worth $3,250,158. Corporate insiders own 0.12% of the company's stock.